{"pmid":32316713,"title":"[Clinical Characteristics and Coping Strategies of Neoplasms with 2019 Novel Coronavirus Infection].","text":["[Clinical Characteristics and Coping Strategies of Neoplasms with 2019 Novel Coronavirus Infection].","Since mid-December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has outbroken in Wuhan, Hubei Province, China, and spread rapidly to other provinces in China and dozens of countries and regions around the world, becoming the Public Health Emergency of International Concern (Public Health Emergency of International Concern). SARS-CoV-2 can mainly transmit by droplets or close contact, and is generally susceptible in the crowd. Tumor patients are at high risk of this pathogen because of their impaired immune function. Identifying tumor patients with 2019 novel coronavirus disease (COVID-19) early, and understanding its distribution characteristics can help to improve the cure rate of patients, and better control the epidemic and development of SARS-CoV-2 much better. With comprehensive analysis of relevant literature, this paper reviews the clinical characteristics of neoplastic patients with COVID-19, and puts forward some suggestions on how to deal with this epidemic.","Zhongguo Fei Ai Za Zhi","Zhao, Nannan","Shi, Jie","Zeng, Lizhong","Yang, Shuanying","32316713"],"abstract":["Since mid-December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has outbroken in Wuhan, Hubei Province, China, and spread rapidly to other provinces in China and dozens of countries and regions around the world, becoming the Public Health Emergency of International Concern (Public Health Emergency of International Concern). SARS-CoV-2 can mainly transmit by droplets or close contact, and is generally susceptible in the crowd. Tumor patients are at high risk of this pathogen because of their impaired immune function. Identifying tumor patients with 2019 novel coronavirus disease (COVID-19) early, and understanding its distribution characteristics can help to improve the cure rate of patients, and better control the epidemic and development of SARS-CoV-2 much better. With comprehensive analysis of relevant literature, this paper reviews the clinical characteristics of neoplastic patients with COVID-19, and puts forward some suggestions on how to deal with this epidemic."],"journal":"Zhongguo Fei Ai Za Zhi","authors":["Zhao, Nannan","Shi, Jie","Zeng, Lizhong","Yang, Shuanying"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32316713","week":"202017|Apr 20 - Apr 26","doi":"10.3779/j.issn.1009-3419.2020.102.15","keywords":["2019 novel coronavirus disease (covid-19)","sars-cov-2","tumor"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Wuhan","Hubei","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664815087616000000,"score":8.518259,"similar":[{"pmid":32291542,"title":"The epidemiology and clinical information about COVID-19.","text":["The epidemiology and clinical information about COVID-19.","In December 2019, pneumonia of unknown cause occurred in Wuhan, Hubei Province, China. On 7 January 2020, a novel coronavirus, named as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was identified in the throat swab sample of one patient. The World Health Organization (WHO) announced the epidemic disease caused by SARS-CoV-2 as coronavirus disease 2019 (COVID-19). Currently, COVID-19 has spread widely around the world, affecting more than seventy countries. China, with a huge burden of this disease, has taken strong measures to control the spread and improve the curative rate of COVID-19. In this review, we summarized the epidemiological characteristics, clinical features, diagnosis, treatment, and prognosis of COVID-19. A comprehensive understanding will help to control the disease.","Eur J Clin Microbiol Infect Dis","Ge, Huipeng","Wang, Xiufen","Yuan, Xiangning","Xiao, Gong","Wang, Chengzhi","Deng, Tianci","Yuan, Qiongjing","Xiao, Xiangcheng","32291542"],"abstract":["In December 2019, pneumonia of unknown cause occurred in Wuhan, Hubei Province, China. On 7 January 2020, a novel coronavirus, named as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was identified in the throat swab sample of one patient. The World Health Organization (WHO) announced the epidemic disease caused by SARS-CoV-2 as coronavirus disease 2019 (COVID-19). Currently, COVID-19 has spread widely around the world, affecting more than seventy countries. China, with a huge burden of this disease, has taken strong measures to control the spread and improve the curative rate of COVID-19. In this review, we summarized the epidemiological characteristics, clinical features, diagnosis, treatment, and prognosis of COVID-19. A comprehensive understanding will help to control the disease."],"journal":"Eur J Clin Microbiol Infect Dis","authors":["Ge, Huipeng","Wang, Xiufen","Yuan, Xiangning","Xiao, Gong","Wang, Chengzhi","Deng, Tianci","Yuan, Qiongjing","Xiao, Xiangcheng"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291542","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s10096-020-03874-z","keywords":["clinical","coronavirus disease 2019","epidemiology","pathology","severe acute respiratory syndrome coronavirus-2","treatment"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"locations":["Wuhan","Hubei","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636192462733312,"score":137.18152},{"pmid":32270568,"title":"Treating head and neck tumors during the SARS-CoV-2 epidemic, 2019-2020: Sichuan Cancer Hospital.","text":["Treating head and neck tumors during the SARS-CoV-2 epidemic, 2019-2020: Sichuan Cancer Hospital.","Since December 2019, a number of patients with novel coronavirus pneumonia (NCP) have been identified in Wuhan, Hubei Province, China. NCP has rapidly spread to other provinces and cities in China and other countries in the world. Due to the rapid increase in reported cases in China and around the world, on January 30, 2020, the World Health Organization (WHO) Emergency Committee announced that NCP is a Public Health Emergency of International Concern (PHEIC). However, there are relatively few suggestions and measures for tumor patients, especially patients with head and neck tumors. This article summarizes the prevention and control of disease in our medical institution to provide a reference for front-line head and neck surgeons. This article is protected by copyright. All rights reserved.","Head Neck","Cai, Yong-Cong","Wang, Wei","Li, Chao","Zeng, Din-Fen","Zhou, Yu-Qiu","Sun, Rong-Hao","Jiang, Hua","Guo, Hui","Wang, Shao-Xin","Jiang, Jian","32270568"],"abstract":["Since December 2019, a number of patients with novel coronavirus pneumonia (NCP) have been identified in Wuhan, Hubei Province, China. NCP has rapidly spread to other provinces and cities in China and other countries in the world. Due to the rapid increase in reported cases in China and around the world, on January 30, 2020, the World Health Organization (WHO) Emergency Committee announced that NCP is a Public Health Emergency of International Concern (PHEIC). However, there are relatively few suggestions and measures for tumor patients, especially patients with head and neck tumors. This article summarizes the prevention and control of disease in our medical institution to provide a reference for front-line head and neck surgeons. This article is protected by copyright. All rights reserved."],"journal":"Head Neck","authors":["Cai, Yong-Cong","Wang, Wei","Li, Chao","Zeng, Din-Fen","Zhou, Yu-Qiu","Sun, Rong-Hao","Jiang, Hua","Guo, Hui","Wang, Shao-Xin","Jiang, Jian"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32270568","week":"202015|Apr 06 - Apr 12","doi":"10.1002/hed.26161","keywords":["2019 novel coronavirus diseases","head and neck tumor","infectious diseases","medical protection"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Wuhan","Hubei","China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637315670081536,"score":133.36336},{"pmid":32243668,"title":"A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.","text":["A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.","The outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread globally since being identified as a public health emergency of major international concern and has now been declared a pandemic by the World Health Organization (WHO). In December 2019, an outbreak of atypical pneumonia, known as COVID-19, was identified in Wuhan, China. The newly identified zoonotic coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is characterized by rapid human-to-human transmission. Many cancer patients frequently visit the hospital for treatment and disease surveillance. They may be immunocompromised due to the underlying malignancy or anticancer therapy and are at higher risk of developing infections. Several factors increase the risk of infection, and cancer patients commonly have multiple risk factors. Cancer patients appear to have an estimated twofold increased risk of contracting SARS-CoV-2 than the general population. With the WHO declaring the novel coronavirus outbreak a pandemic, there is an urgent need to address the impact of such a pandemic on cancer patients. This include changes to resource allocation, clinical care, and the consent process during a pandemic. Currently and due to limited data, there are no international guidelines to address the management of cancer patients in any infectious pandemic. In this review, the potential challenges associated with managing cancer patients during the COVID-19 infection pandemic will be addressed, with suggestions of some practical approaches. This article is protected by copyright. All rights reserved.","Oncologist","Al-Shamsi, Humaid O","Alhazzani, Waleed","Alhuraiji, Ahmad","Coomes, Eric A","Chemaly, Roy F","Almuhanna, Meshari","Wolff, Robert","Nuhad, Ibrahim K","Chua, Melvin L K","Hotte, Sebastien J","Meyers, Brandon M","Elfiki, Tarek","Curigliano, Giuseppe","Eng, Cathy","Grothey, Axel","Xie, Conghua","32243668"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread globally since being identified as a public health emergency of major international concern and has now been declared a pandemic by the World Health Organization (WHO). In December 2019, an outbreak of atypical pneumonia, known as COVID-19, was identified in Wuhan, China. The newly identified zoonotic coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is characterized by rapid human-to-human transmission. Many cancer patients frequently visit the hospital for treatment and disease surveillance. They may be immunocompromised due to the underlying malignancy or anticancer therapy and are at higher risk of developing infections. Several factors increase the risk of infection, and cancer patients commonly have multiple risk factors. Cancer patients appear to have an estimated twofold increased risk of contracting SARS-CoV-2 than the general population. With the WHO declaring the novel coronavirus outbreak a pandemic, there is an urgent need to address the impact of such a pandemic on cancer patients. This include changes to resource allocation, clinical care, and the consent process during a pandemic. Currently and due to limited data, there are no international guidelines to address the management of cancer patients in any infectious pandemic. In this review, the potential challenges associated with managing cancer patients during the COVID-19 infection pandemic will be addressed, with suggestions of some practical approaches. This article is protected by copyright. All rights reserved."],"journal":"Oncologist","authors":["Al-Shamsi, Humaid O","Alhazzani, Waleed","Alhuraiji, Ahmad","Coomes, Eric A","Chemaly, Roy F","Almuhanna, Meshari","Wolff, Robert","Nuhad, Ibrahim K","Chua, Melvin L K","Hotte, Sebastien J","Meyers, Brandon M","Elfiki, Tarek","Curigliano, Giuseppe","Eng, Cathy","Grothey, Axel","Xie, Conghua"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243668","week":"202014|Mar 30 - Apr 05","doi":"10.1634/theoncologist.2020-0213","keywords":["covid-19","coronavirus","influenza","neoplasm","pandemic","sars-cov-2"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664638249291743232,"score":131.24168},{"pmid":32306656,"title":"[Clinical consideration and management of coronavirus disease 2019].","text":["[Clinical consideration and management of coronavirus disease 2019].","Coronavirus disease 2019 (COVID-19) outbreak in Wuhan city, Hubei province in December 2019 and the epidemic so rapidly happened within the whole country and abroad, raising serious problems and urgent concerns, such as: how to control most effectively human-to-human transmission? When does infection rate rise to its peak? What will eventually be the number of infected patients? How to make early diagnosis? What effective antiviral drugs are available? How to use the existing drugs to achieve the best effect? Can available drugs effectively improve the survival rate of critical patients? In view of the above questions, this article now puts forwards the corresponding suggestions and considerations from the perspective of clinical infectious diseases physician.","Zhonghua Gan Zang Bing Za Zhi","Ma, K","Chen, T","Han, M F","Guo, W","Ning, Q","32306656"],"abstract":["Coronavirus disease 2019 (COVID-19) outbreak in Wuhan city, Hubei province in December 2019 and the epidemic so rapidly happened within the whole country and abroad, raising serious problems and urgent concerns, such as: how to control most effectively human-to-human transmission? When does infection rate rise to its peak? What will eventually be the number of infected patients? How to make early diagnosis? What effective antiviral drugs are available? How to use the existing drugs to achieve the best effect? Can available drugs effectively improve the survival rate of critical patients? In view of the above questions, this article now puts forwards the corresponding suggestions and considerations from the perspective of clinical infectious diseases physician."],"journal":"Zhonghua Gan Zang Bing Za Zhi","authors":["Ma, K","Chen, T","Han, M F","Guo, W","Ning, Q"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32306656","week":"202017|Apr 20 - Apr 26","doi":"10.3760/cma.j.cn50113-20200220-00056","keywords":["2019 novel coronavirus","covid-19","diagnosis","treatment"],"source":"PubMed","topics":["Prevention","Treatment","Diagnosis"],"weight":1,"locations":["Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664632501355675649,"score":126.42},{"pmid":32237160,"title":"Epidemiological analysis of COVID-19 and practical experience from China.","text":["Epidemiological analysis of COVID-19 and practical experience from China.","The rapid spread of the epidemic has aroused widespread concern in the international community. Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) originated from Wuhan's Huanan wholesale seafood market, with bats as the likely original hosts and pangolins as potential intermediate hosts. The current source of the disease is mainly patients infected with SARS-COV-2. Patients in the incubation period may also become sources of infection. The virus is mainly transmitted via respiratory droplets and contact, and the population is generally susceptible. The epidemic has progressed through the local outbreak stage and community transmission stage due to exposure at Wuhan's Huanan wholesale seafood market and is now in the stage of large-scale transmission due to the spread of the epidemic. The basic productive number (R0) at the beginning of the epidemic was 2.2, with an average incubation period of 5.2 days. The proportion of critically ill patients was 23.4%, the mortality rate was lower than those of SARS and Middle East respiratory syndrome, and 96.5% of deaths occurred in Hubei Province, where the outbreak occurred first. Among them, elderly men with underlying diseases had a higher mortality rate. Chinese medical staff have summarized a set of effective strategies and methods in the diagnosis and treatment of this disease that are worthy of reference for their international counterparts. With powerful government intervention and the efforts of Chinese medical staff, China's outbreak has gradually improved.","J Med Virol","Ye, Qing","Wang, Bili","Mao, Jianhua","Fu, Junfen","Shang, Shiqiang","Shu, Qiang","Zhang, Ting","32237160"],"abstract":["The rapid spread of the epidemic has aroused widespread concern in the international community. Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) originated from Wuhan's Huanan wholesale seafood market, with bats as the likely original hosts and pangolins as potential intermediate hosts. The current source of the disease is mainly patients infected with SARS-COV-2. Patients in the incubation period may also become sources of infection. The virus is mainly transmitted via respiratory droplets and contact, and the population is generally susceptible. The epidemic has progressed through the local outbreak stage and community transmission stage due to exposure at Wuhan's Huanan wholesale seafood market and is now in the stage of large-scale transmission due to the spread of the epidemic. The basic productive number (R0) at the beginning of the epidemic was 2.2, with an average incubation period of 5.2 days. The proportion of critically ill patients was 23.4%, the mortality rate was lower than those of SARS and Middle East respiratory syndrome, and 96.5% of deaths occurred in Hubei Province, where the outbreak occurred first. Among them, elderly men with underlying diseases had a higher mortality rate. Chinese medical staff have summarized a set of effective strategies and methods in the diagnosis and treatment of this disease that are worthy of reference for their international counterparts. With powerful government intervention and the efforts of Chinese medical staff, China's outbreak has gradually improved."],"journal":"J Med Virol","authors":["Ye, Qing","Wang, Bili","Mao, Jianhua","Fu, Junfen","Shang, Shiqiang","Shu, Qiang","Zhang, Ting"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32237160","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25813","keywords":["covid-19","epidemic","mortality","treatment","virus pneumonia"],"source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"locations":["Wuhan","Huanan","Wuhan","Huanan","Hubei","Chinese","Chinese","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664638354184994817,"score":125.338615}]}